New York, NY (September 03, 2010) – Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I/II clinical research study of an investigational vaccine for HIV.
According to Dr. Howard Greenberg, Senior Medical Director of Clinilabs, “Conducting early phase clinical trials with a novel therapeutic in a new patient population is a major advance in Clinilabs’ progression as a CRU.” Greenberg also notes that conducting vaccine studies and expanding enrollment of specialty patient populations are two key strategic directions Clinilabs is pursuing to capitalize on its unique position as a global CRO that operates a CRU in New York City, a hub of academic medical centers and home to a diverse population of more than 19 million potential research subjects.
Enrollment for this study is expected to begin later this month. Individuals in the New York City Metro area who are interested in participation may contact our dedicated recruitment staff at 212-994-4567 to prequalify. Healthy adult volunteers as well as HIV positive individuals who have a T-Cell count of 500 or more, may be eligible. Additional information may also be found by visiting www.clinilabs.com/volunteers.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.
For more information or to schedule an interview, please contact Jeanine Estrada at 646.450.2215 or e-mail jestrada@clinilabs.com.
